Barclays PLC boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 42.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 115,671 shares of the company's stock after purchasing an additional 34,533 shares during the period. Barclays PLC owned 0.20% of Structure Therapeutics worth $3,138,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of GPCR. Geode Capital Management LLC increased its stake in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after acquiring an additional 312 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the last quarter. LPL Financial LLC grew its stake in shares of Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after acquiring an additional 843 shares in the last quarter. Finally, Money Concepts Capital Corp raised its holdings in Structure Therapeutics by 4.2% during the fourth quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock valued at $570,000 after buying an additional 848 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. William Blair assumed coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Citigroup initiated coverage on Structure Therapeutics in a research note on Friday. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $78.63.
Read Our Latest Stock Report on GPCR
Structure Therapeutics Stock Performance
Shares of NASDAQ:GPCR traded down $0.81 during trading on Monday, hitting $26.29. 61,681 shares of the stock were exchanged, compared to its average volume of 919,585. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -35.93 and a beta of -1.35. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company's fifty day simple moving average is $20.52 and its 200-day simple moving average is $27.30.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.
About Structure Therapeutics
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
